Brett P. Giroir (born November 4, 1960) is an American pediatrician and a four-star admiral in the U.S. Public Health Service Commissioned Corps, who currently serves as the Assistant Secretary for Health under the Trump administration. He concurrently serves as the Secretary's principal public health and science adviser, senior adviser for HRSA, CDC, and SAMHSA and chief opioid policy adviser. He also served as the Acting Commissioner of Food and Drugs in November and December of 2019, while Stephen Hahn's nomination was pending in the Senate. Giroir has also been nominated by the President to serve the additional role of the representative of the United States on the executive board of the World Health Organization. The nomination was returned to the President on January 3, 2020 without action. Giroir has led major initiatives for academic institutions, global corporations, and the U.S. Departments of Defense, Health and Human Services, and Veterans Affairs. He served as president and CEO of ViraCyte, LLC, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections and as senior fellow at the Texas Medical Center Health Policy Institute and strategic advisor for the Texas Medical Center Innovation Institute (TMCx). He was a member of the Texas Task Force for Infectious Disease Preparedness and Response (charted initially by the governor to respond to Texas Ebola cases), adjunct professor of pediatrics, tropical medicine, and medical ethics and health policy at the Baylor College of Medicine. Giroir chaired the independent Blue Ribbon Panel for the Veterans Choice and Accountability Act of 2014, whose comprehensive assessment and recommendations to reform the Veterans Administration Health System were delivered to Congress and Secretary Robert McDonald on September 1, 2015. He subsequently testified to the full House Committee on Veterans Affairs on October 7, 2015, and communicated priorities for VA reform in the New England Journal of Medicine. Giroir served as the deputy director, and then a director, of DARPA's Defense Science Office from 2004 to 2008, vice chancellor for the Texas A&M University System from 2008 to 2013, and as the chief executive officer of the Texas A&M Health Science Center from 2013 to 2015. He is widely known for leading novel biomedical initiatives within Texas culminating in the 2012 announcement of a public private partnership with the U.S. Department of Health and Human Service Biomedical Research and Development Authority to accelerate development and manufacturing of vaccines and therapeutics for pandemic influenza and emerging infectious diseases. This partnership had a $3 billion contract value over 25 years, with an estimated $41 billion in economic impact to Texas.